Archive for the ‘Compounding API’ Category

Metformin HCL (Hydrochloride) & Recent Studies

Wednesday, December 8th, 2010

Metformin HCLMetformin HCL is one of the most recommended medicines for the treatment of patients suffering from biguanide or type 2 Diabetes. According to recent studies, Metformin Hydrochloride reduces the LDL and triglyceride levels in the blood and hence it is one of the best medicines for diabetic patients who are also suffering with obesity. Studies are being performed to establish Metformin Hydrochloride as an efficient solution for the issues of patients suffering from gestational diabetes.

Importance of Metformin Hydrochloride as the first choice for Diabetic patients

This oral anti-diabetic drug has established itself as one of the major anti-diabetic drug throughout the world. In the year 2009, 42 million prescriptions were made for U.S patients suffering from type 2 Diabetes. Some researches reveal that during the study period of 10 years, patients who used Metformin, improved against the diabetes complications and mortality rate by 30% when compared with the results in patients who were treated with sulfonylureas and insulin. The same results for the patients treated with Metformin were better by 40% when compared with the patients who were prescribed to maintain dietary control alone.

Metformin HCL is usually the first drug of choice for most patients suffering from diabetes and obesity. This is primarily because Metformin causes very little to no weight gain at all, and lessens the chances of hpoglycaemic attacks in the patient. This differs greatly from sulphonylureas and insulin which cause significant weight gain and risks of hypoglycaemic attacks.

Further uses of Metformin HCL

With the recent success of experiments that indicates that Metformin can be efficient to alleviate issues related with premature puberty, non-alcoholic fatty liver disease and polycystic ovary syndrome, Metformin HCL is gaining popularity as a common drug with the least side effects and efficient results.

During a study conducted on mice, scientists established that Metformin can also play an effective role on controlling tobacco-induced lung cancer. In September 2010, Cancer Prevention Research published a report mentioning that Metformin Hydrochloride was found effective to reduce the number of tumor in mice by 73%. The tumors in mice were caused with the effect of common carcinogen found in tobacco.

Thus, apart from being a highly recommended drug for type 2 Diabetic patients suffering from obesity, Metformin HCL may soon be used as a drug to cure tobacco-induced lung cancer.

LGM Pharma is a US based supplier of the API (Active Pharmaceutical Ingredient) Metformin HCL for research and development purposes.  Inquire about Metformin HCL prices, availability, delivery, purity and more.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Sulfonylurea Class Antidiabetic Drugs

Tuesday, November 23rd, 2010

Anti-diabetic drugs treat diabetes by lowering glucose levels in the blood.  One class of anti-diabetic drugs that are used in the management of diabetes is Sulfonylurea.  Sulfonylurea derivatives are used in the management of diabetes mellitus type 2.  They act by increasing insulin release from the beta cells in the pancreas.  Diabetes mellitus type 2 is a disease of insulin resistance by cells.  Treatments include agents which increase the amount of insulin secreted by the pancreas, agents which increase the sensitivity of target organs to insulin, and agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract.

LGM Pharma is a US based supplier of the following APIs (Active Pharmaceutical Ingredients) from the Sulfonylurea class of Anti-diabetic drugs, for research and development purposes:

First generation

  • Acetohexamide – used mainly for people whose diabetes cannot be controlled by diet alone.
  • Chlorpropamide – a long-acting sulphonylurea. It has more side effects than other sulphonylureas and its use is no longer recommended.
  • Tolbutamide – generally has a short duration of action due to its rapid metabolism, and is therefore safe for use in elderly diabetics.
  • Tolazamide – other diabetes medicines are sometimes used in combination with tolazamide if needed.

Second generation

  • Glipizide – is an oral medium-to-long acting anti-diabetic drug.
  • Gliclazide – classification has been ambiguous, as literature uses it as both a first-generation and second-generation sulfonylurea.
  • Glibenclamide (glyburide) – a major cause of drug induced hypoglycemia. Cholestatic jaundice is noted.
  • Gliquidone – in addition to its primary function, it assists on the movement of sugar in the blood into the cells in the body.

Third generation

  • Glimepiride – also is available in combination with other diabetes medications such as Rosiglitazone.

Check out our other Popular Research Chemicals, and find the right products to assist you with your R&D needs.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Compounding Active Pharmaceutical Ingredients (API)

Wednesday, October 13th, 2010

compounding-apiPharmaceutical compounding is a branch of pharmacy that continues to play a crucial role in drug development. Compounding pharmacists and medicinal chemists develop and test pharmaceutical formulations for new drugs so that the active ingredients are effective, stable, easy to use, and acceptable to patients.

LGM Pharma supplies high quality active pharmaceutical ingredients to pharmaceutical companies in the U.S. and worldwide.

When compounding, it is essential to precisely measure the Compounding API to supply the highest quality.

In turn, we calculate the Assay Value, Base Form & Salt Form, and Moisture Content when measuring the Compounding API.

Check out our Compounding Products >

LGM Pharma Supplies Ingredients for Several Obesity Drugs

Tuesday, August 31st, 2010

obesity-in-americaTwo-thirds of Americans are obese or overweight, according to the Centers for Disease Control and Prevention.

The US Food and Drug Administration plans on reviewing three new anti-obesity drugs by the end of 2010. The FDA will announce its decision on two of these drugs within the next few months.

LGM Pharma is a US based supplier of the following APIs (Active Pharmaceutical Ingredients) for research and development purposes:

The combination of the drugs Phentermine and Topiramate (trade name Qnexa). It is an investigational medication for the treatment of obesity and related conditions such as type 2 diabetes. It has been found to lower blood pressure and cholesterol. FDA’s advisory committee voted not to approve Qnexa due to the potential side effects of the drug.

Another obesity drug is a combination of the two approved drugs Bupropion and Naltrexone. In clinical trials, patients taking the sustained-release formulation (trade name Contrave) combined with diet and exercise, lost more weight than patients taking a placebo following the same diet and exercise program.

Lorcaserin is different from the previous two anti-obesity drugs under review in that it is a new molecule, not a combination of existing, approved medications. FDA’s advisory panel will meet on Sept. 16, 2010, to discuss Lorcaserin, and Oct. 22, 2010, is the PDUFA date (one week before Qnexa).

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Nalbuphine HCL

Thursday, August 12th, 2010

Nalbuphine HCLNalbuphine HCL cas# 23277-43-2 (Nalbuphine Hydrochloride) is a synthetic opioid used commercially as an analgesic under a variety of trade names, including Nubain. It is noteworthy in part for the fact that at low dosages, it is found much more effective by women than by men, and may even increase pain in men, leading to its discontinuation in the UK in 2003.

Inquire about Nalbuphine HCL price and availability >

LGM Pharma’s team of Compounding API’s task managers have extensive knowledge of Nalbuphine. Our expert knowledge of products allows us to keep a close eye on our competitors. We also adhere to the latest FDA/CVM rulings and regulations such as being CGMP Certified, and by using FDA approved supply sources with registered NDC#’s.

Our Compounding Products are geared specifically for the Compounding Industry. All of our superior quality API’s are from GMP certified and US-FDA registered manufacturers with NDC listings. All products are supplied in original manufacturers packing, with the manufacturer’s labels and NDC details.

If you would like to compound a product that is not on LGM Pharma’s Compounding Products list, contact us, and our excellent customer support will assist you with your requirements.

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.